APA (7th ed.) Citation

MS, H., JK, T., X, Y., H, B., S, S., M, R., . . . S, P. (2023). Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients. Journal for immunotherapy of cancer, 11(10), . https://doi.org/10.1136/jitc-2023-007288

Chicago Style (17th ed.) Citation

MS, Hall, et al. "Neoantigen-specific CD4+ Tumor-infiltrating Lymphocytes Are Potent Effectors Identified Within Adoptive Cell Therapy Products for Metastatic Melanoma Patients." Journal for Immunotherapy of Cancer 11, no. 10 (2023). https://doi.org/10.1136/jitc-2023-007288.

MLA (9th ed.) Citation

MS, Hall, et al. "Neoantigen-specific CD4+ Tumor-infiltrating Lymphocytes Are Potent Effectors Identified Within Adoptive Cell Therapy Products for Metastatic Melanoma Patients." Journal for Immunotherapy of Cancer, vol. 11, no. 10, 2023, https://doi.org/10.1136/jitc-2023-007288.